Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$360.59M-5.3% | -$342.6M-13.5% | -$301.97M+12.2% | -$344.06M-11.6% | -$308.32M-14.2% | ||
| $464K+0.9% | $460K-0.6% | $463K-4.1% | $483K-5.7% | $512K-5.2% | ||
| $47.47M+7.2% | $44.3M+7.3% | $41.29M+6.5% | $38.76M-2.3% | $39.68M-5.9% | ||
| -$303.39M-9.8% | -$276.39M+15.2% | -$325.97M-5.5% | -$309.06M-10.5% | -$279.75M-20.4% | ||
| $432K-12.7% | $495K+34.1% | $369K-31.0% | $535K-10.4% | $597K+16.8% | ||
| -$60.36M-60.7% | -$37.56M-116% | $238.94M+747% | $28.2M— | —— | ||
| $423.89M-0.7% | $426.74M+657% | $56.36M-80.6% | $290.52M+0.2% | $289.87M-36.7% | ||
| $60.13M-46.7% | $112.79M+468% | -$30.67M-418% | $9.66M-60.7% | $24.57M+860% | ||
| -$303.82M-9.7% | -$276.89M+15.2% | -$326.34M-5.4% | -$309.6M-10.4% | -$280.35M-20.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.